NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
UNITED STATES
OMB APPROVAL
OMB Number: 3235-0080
Expires: December 31, 2014
Estimated average burden
hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-33818
Issuer: ReShape Lifesciences Inc.
Exchange: The Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 1001 Calle Amanecer
San Clemente CALIFORNIA 92673
Telephone number: 651 634-3003
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1)
17 CFR 240.12d2-2(a)(2)
17 CFR 240.12d2-2(a)(3)
17 CFR 240.12d2-2(a)(4)
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, The Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2019-03-12 By Amy Horton Hearings Advisor
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Delisting Determination,The Nasdaq Stock Market, LLC,
March 11, 2019, ReShape Lifesciences Inc. The Nasdaq 
Stock Market, Inc. (the Exchange) has determined to remove 
from listing the common stock of ReShape Lifesciences Inc.
(the Company), effective at the opening of the trading 
session on March 22, 2019. Based on review of information 
provided by the Company, Nasdaq Staff determined that the 
Company no longer qualified for listing on the Exchange 
pursuant to Listing Rules 5101 and 5550(a)(2). 
The Company was notified of the Staffs determination on 
October 29, 2018.  The Company appealed the determination 
to a Hearing Panel. Upon review of the information provided 
by the Company, the Panel issued a decision dated 
December 27, 2018, denying the Company continued listing 
and notified the Company that trading in the Companys 
securities would be suspended on December 31, 2018. 
The Company did not request a review of the Panels decision 
by the Nasdaq Listing and Hearing Review Council. The 
Listing Council did not call the matter for review. 
The Panels Determination to delist the Company 
became final on February 11, 2019.